Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2030

(ALBANY, US) DELVEINSIGHT HA S LAUNCHED A NEW REPORT ON Traumatic Brain Injury Market

DelveInsight’s Tuberous Sclerosis Complex  Market Insights, Epidemiology, and Market Forecast 2030 report delivers an in-depth understanding of the Tuberous Sclerosis Complex , historical and forecasted epidemiology as well as the Tuberous Sclerosis Complex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Tuberous Sclerosis Complex market report provides current treatment practices, emerging drugs, Tuberous Sclerosis Complex market share of the individual therapies, current and forecasted Tuberous Sclerosis Complex market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Tuberous Sclerosis Complex treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Tuberous Sclerosis Complex Market
Tuberous Sclerosis Complex Market

Click Here For Free Sample Page:- https://www.delveinsight.com/sample-request/tuberous-sclerosis-complex-market

Tuberous Sclerosis Complex Market Outlook

The Tuberous Sclerosis Complex market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Tuberous Sclerosis Complex market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Tuberous Sclerosis Complex market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Tuberous Sclerosis Complex market in 7MM is expected to change in the study period 2017-2030

KEY FACT FROM THE REPORT

  • Approximately, 2.8 million people sustain TBI annually in the United States and every day 153 people in the United States die from injuries that include TBI as per Brain line organization.
  • Centers for Disease Control and Prevention reported that over the span of six years (2007–2013) TBI- related ED visits have increased by 47%, hospitalization rates decreased by 2.5% and death rates decreased by 5%.
  • Marek Majdan et al. estimated that about 57,000 TBI-related deaths and 1·5 million hospital discharges occurred in 2012 in Europe.
  • According to data from the Overall Analysis Center of Traffic Accidents, TBI accounts for 9.3% of 1,160,000 traffic.

 

MAJOR KEY PLAYERS OF THE REPORT

  • Vasopharm GmBH
  • NeuroVive Pharmaceutical AB
  • Cellvation Therapeutics

 

NAME OF DRUGS COVERED IN THE REPORT

  • Ronopterin (VAS203)
  • NeuroSTAT
  • CEVA101

 

Table of content

1. Key Insights

2. Executive Summary of Tuberous Sclerosis Complex

3. Competitive Intelligence Analysis for Tuberous Sclerosis Complex

4. Tuberous Sclerosis Complex : Market Overview at a Glance

4.1. Tuberous Sclerosis Complex Total Market Share (%) Distribution in 2017

4.2. Tuberous Sclerosis Complex Total Market Share (%) Distribution in 2030

5. Tuberous Sclerosis Complex : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Tuberous Sclerosis Complex Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Tuberous Sclerosis Complex Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Tuberous Sclerosis Complex Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Tuberous Sclerosis Complex Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Tuberous Sclerosis Complex Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Tuberous Sclerosis Complex Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Tuberous Sclerosis Complex Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Tuberous Sclerosis Complex Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Tuberous Sclerosis Complex Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Tuberous Sclerosis Complex Treatment and Management

8.2. Tuberous Sclerosis Complex Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Tuberous Sclerosis Complex Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

13. Tuberous Sclerosis Complex : Seven Major Market Analysis

13.1. Key Findings

13.2. Tuberous Sclerosis Complex Market Size in 7MM

13.3. Tuberous Sclerosis Complex Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Tuberous Sclerosis Complex Total Market Size in the United States

15.1.2. Tuberous Sclerosis Complex Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Tuberous Sclerosis Complex Total Market Size in Germany

15.3.2. Tuberous Sclerosis Complex Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Tuberous Sclerosis Complex Total Market Size in France

15.4.2. Tuberous Sclerosis Complex Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Tuberous Sclerosis Complex Total Market Size in Italy

15.5.2. Tuberous Sclerosis Complex Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Tuberous Sclerosis Complex Total Market Size in Spain

15.6.2. Tuberous Sclerosis Complex Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Tuberous Sclerosis Complex Total Market Size in the United Kingdom

15.7.2. Tuberous Sclerosis Complex Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Tuberous Sclerosis Complex Total Market Size in Japan

15.8.3. Tuberous Sclerosis Complex Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Tuberous Sclerosis Complex

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

 

ABOUT DELVEINSIGHT 

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

CONTACT US:

Shruti Thakur
[email protected]
+91-9650213330

Related posts